Drug intelligence / Profile preview

BL-5010

Development stage
Unknown
Lead developer
BioLineRx
Modality
Small Molecules
Administration
Topical
01

Overview

BL-5010 is a topical aqueous fixed-dose formulation of **trichloroacetic acid** and **formic acid** developed for non-surgical removal of benign skin lesions, principally seborrheic keratosis. The formulation acts as a localized chemical escharotic and keratolytic: following direct lesion application, it causes controlled chemical injury, dehydration, coagulative necrosis, and progressive separation of the lesion from underlying skin. BioLineRx developed BL-5010 under an exclusive license from Innovative Pharmaceutical Concepts; a multicenter Phase I/II study in 60 patients with seborrheic keratosis reported high lesion-clearance rates and favorable cosmetic outcomes. The product subsequently received CE Mark approval in Europe as an over-the-counter Class IIa medical-device treatment for non-surgical skin-lesion removal.

Other names
BL 5010BL5010BL-5010

Beyond the preview

Go deeper on BL-5010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-5010.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call